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Abstract
Objective—The objective of the study was to examine the association between provider-patient 
communication, glaucoma medication adherence self-efficacy, outcome expectations, and 
glaucoma medication adherence.
Design—Prospective observational cohort study.
Participants—279 patients with glaucoma who were newly prescribed or on glaucoma 
medications were recruited at six ophthalmology clinics.
Methods—Patients’ visits were video-tape recorded and communication variables were coded 
using a detailed coding tool developed by the authors. Adherence was measured using Medication 
Event Monitoring Systems for 60 days after their visits.
Main outcome measures—The following adherence variables were measured for the 60 day 
period after their visits: whether the patient took 80% or more of the prescribed doses, percent 
correct number of prescribed doses taken each day, and percent prescribed doses taken on time.
Results—Higher glaucoma medication adherence self-efficacy was positively associated with 
better adherence with all three measures. African American race was negatively associated with 
percent correct number of doses taken each day (beta= −0.16, p<0.05) and whether the patient 
took 80% or more of the prescribed doses (odds ratio=0.37, 95% confidence interval 0.16, 0.86). 
Physician education about how to administer drops was positively associated with percent correct 
number of doses taken each day (beta= 0.18, p<0.01) and percent prescribed doses taken on time 
(beta=0.15, p<0.05).
Conclusions—These findings indicate that provider education about how to administer 
glaucoma drops and patient glaucoma medication adherence self-efficacy are positively associated 
with adherence.
Glaucoma is one of the leading causes of blindness and visual disability. An estimated 1.5 
million Americans suffer from glaucoma while approximately 120,000 of them have been 
blinded by the disease. Between 9 and 12% of all blindness in the United States is attributed 
to glaucoma.1 A primary goal of glaucoma treatment is to reduce intraocular pressure.2,3 
Taking available glaucoma medications can significantly lower intraocular pressure and 
reduce the progression of glaucoma.4,5 However, despite the availability of medications, 
non-adherence with using glaucoma medications is a significant problem.6
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Each class of topical glaucoma medications has different side effects profiles and some 
patients may tolerate certain side effects better than others.7–11 Additionally, eye drops are 
often difficult to administer.10, 12, 13 Therefore, provider-patient communication about 
glaucoma and glaucoma medications is important and can potentially impact adherence. 
Two qualitative studies reported that poor communication between glaucoma patients and 
their providers negatively impacted adherence.14, 15 Unfortunately, these studies did not 
investigate actual communication.14, 15 One prior study did examine ophthalmologist and 
patient communication during 50 video-taped glaucoma visits but the researchers did not 
report how certain aspects of provider-patient communication were associated with patient 
adherence.16
One prior study found that patients who reported being less likely to ask their eye doctor 
questions during visits also reported being less adherent to their glaucoma medications.17 
Patient question-asking is important because it is a form of active patient participation 
during medical visits in which patients can ask for more information.18, 19 Patient question-
asking can potentially improve patient self-efficacy in managing glaucoma, because if 
patients ask questions about how to correctly use eye drops or resolve problems in using 
glaucoma medications, they can receive information from the doctor and gain more 
confidence in managing their glaucoma.12,20,21
In addition to provider-patient communication, patient self-efficacy, which is one of the key 
constructs of Social Cognitive Theory (SCT), has been found to be significantly associated 
with glaucoma medication adherence in prior research.20,22 Additionally, studies in HIV, 
diabetes, asthma, and depression have found positive associations between self-efficacy and 
medication adherence.23–29 Self-efficacy is defined as individuals’ personal beliefs regarding 
their capabilities to carry out a specific task to achieve a desired outcome.30,31 Another 
construct of SCT, outcome expectations, could also be associated with patient adherence.32 
Outcome expectations are whether an individual believes certain behaviors (e.g. taking eye 
drops) will have a positive impact on their health condition (e.g. glaucoma).
To our knowledge, no prior study has examined how actual video-taped provider-patient 
communication is associated with adherence measured using Medication Event Monitoring 
Systems (MEMS) caps. Therefore, the purpose of our study is to examine the association 
between provider education about glaucoma and glaucoma medications, patient question-
asking, glaucoma medication adherence self-efficacy, outcome expectations, and adherence 
to glaucoma medications measured electronically (percent doses taken over 60 day period, 




This prospective observational cohort study took place at six geographically distinct 
ophthalmology clinics located in the United States that included private offices (two sites) 
and academic ophthalmology departments (four sites). Patients were enrolled between 
December 2009 and May 2012 and eligibility criteria for enrollment included: the ability to 
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speak and read English, having a diagnosis of glaucoma, and being at least 18 years of age. 
At each site, clinic staff referred eligible patients to clinic-based research assistants, who 
obtained written patient and provider consent. Providers and patients were told that the study 
was about provider-patient communication; they were not told what specific aspects of 
communication were being examined. Providers completed a short demographic 
questionnaire after providing consent. The patient’s medical encounter was video-tape 
recorded and patients were interviewed immediately after their medical visits. Each patient 
was given a large prescription vial with Medication Event Monitoring System (MEMS) cap 
on top for each of their prescribed glaucoma medication.8 The MEMS caps electronically 
assessed patient adherence.8 Patients used the MEMS caps for 60 days after their video-
taped visit. The study was approved by the University of North Carolina Institutional Review 




Patient age was measured as a continuous variable. Self-reported patient race was measured 
a categorical variable (White, African American, Asian, Native American, and Hispanic) 
and then recoded as African American and non-African American. The majority of the non-
African American patient sample was White (91 %). Gender was measured as a 
dichotomous variable. The research assistant recorded whether the patient was prescribed 
glaucoma medication for the first time during the medical visit or was already on glaucoma 
medication before the visit. Also, the research assistant extracted the number of glaucoma 
medications a subject was taking after the baseline visit from the patient’s medical record.
Physician age was measured as a continuous variable and physician gender as a dichotomous 
variable. Self-reported physician race was measured as a categorical variable (White, 
African American, Asian, Native American, and Hispanic).
Self-efficacy and outcome expectation measures
All subjects were administered a 21-item previously validated general glaucoma medication 
adherence self-efficacy questionnaire.20 The general glaucoma medication adherence self-
efficacy questionnaire strongly correlates with self-reported measures of adherence.20 They 
were given three possible response choices for the self-efficacy items: not at all confident 
(coded as 1), somewhat confident (coded as 2), very confident (coded as 3). Scores on the 
glaucoma medication adherence scale could range from 21 (lower self-efficacy) to 63 
(higher self-efficacy). The scale has a Cronbach’s alpha of 0.90 in the current sample. 
Outcome expectations were measured using four items designed to assess how much 
patients believed attending their ophthalmic clinical visits and taking medications would 
help their glaucoma and vision.33 Responses ranged from 1 (not at all) to 9 (extremely) for 
each item. Scores could range from 4 to 36 on the outcome expectations scale. The scale had 
a Cronbach’s alpha of 0.94 in the current sample.
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All medical visit video-tapes were transcribed into text verbatim with identifiers removed. 
The authors developed a detailed coding tool to assess communication over a one-year 
period. The areas for education about glaucoma and glaucoma medications were created 
prior literature and input from the pharmacists and ophthalmologists on the study team.34–36 
Transcripts were reviewed by a research assistant who met twice a month with the 
investigators to develop and refine the coding rules.
Using the coding tool for transcribed medical visits, coders recorded the following: (a) did 
the patient ask a question about glaucoma, (b) did the patient ask a question about glaucoma 
medications, (c) did the provider educate about glaucoma, (d) did the provider educate about 
the purpose of the medications, (e) did the provider educate about the importance of 
adhering to the medication, (f) did the provider educate about side effects, and (g) did the 
provider educate about how to administer the glaucoma medication.
We coded for patient-provider communication variables that have been theoretically and 
empirically linked with adherence self-efficacy and/or medication adherence. Specifically, 
we chose to examine whether the provider educated about how to administer glaucoma 
medications because educating about how to administer the medications could improve 
glaucoma medication adherence self-efficacy which is one of the key components of Social 
Cognitive Theory.30,31 We coded for provider education about glaucoma and provider 
education about glaucoma medication adherence, side effects and medication purpose 
because education about these areas can improve patient knowledge of their disease and how 
to manage it, which could ultimately lead to improved adherence self-efficacy and 
medication adherence. Similarly, we coded for patient question-asking about glaucoma and 
glaucoma medications because, in prior work, patient question-asking has been associated 
with adherence.17
Two clinics had glaucoma fellows examine some of the enrolled patients while two other 
clinics had ophthalmic technicians examine some of the enrolled patients. Informed consent 
was obtained from these providers as well. If any one of these healthcare providers, 
including the physician, educated the patient, it was counted as education in the categories 
discussed above.
Three research assistants coded 25 of the same transcripts throughout the study period to 
calculate inter-rater correlations as a determination of inter-rater reliability. Inter-rater 
reliability was 0.84 for the patient asking a question about glaucoma, 0.78 for the patient 
asking a question about glaucoma medications, 0.76 for the physician educating about 
glaucoma, 0.93 for the physician educating about the purpose of the medication, 0.85 the 
physician educating about adherence and adherence strategies, 0.94 for the physician 
educating about side effects, and 0.95 for the physician educating about how to administer 
the drops.
Adherence measures
Medication adherence over a 60 day period after the video-taped visit was evaluated via 
electronic data from the MEMS caps system (AARDEX).8 The MEMS caps measured the 
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date and time that the patients opened the vial to take their eye drop bottle out to administer 
medication, but they do not measure if the patients actually put their drops in their eyes. 
Whether the patient took 80 percent or more of their prescribed doses was measured from 
the MEMS caps using the following formula: adherence = (number of doses used during the 
past two months divided by the number of prescribed doses) multiplied by 100. We 
dichotomized the variable since it was skewed towards patients being highly adherent. 
Subjects were considered adherent if they used 80% or more of the prescribed doses (79.5% 
or above was rounded to 80% or more) and they were classified as non-adherent if they used 
less than 80% of the prescribed doses as suggested in prior research.37
We also used the electronic data from the MEMS caps to examine the percent doses taken on 
time during the 60 day period after the video-taped visit.8 If patients were on once a day 
dosing, taking it on time was taking it every 24 hours plus or minus 6 hours. If it was twice a 
day dosing, taking it on time was every 12 hours plus or minus 3 hours. We also examined 
using the MEMS caps data the percent correct number of prescribed doses taken each day 
during the 60 day period after the video-taped visit.8
If the subject was on more than one glaucoma medication, for each of the three adherence 
measures, an adherence measure was created for each medication and then an overall 
adherence variable was created by adding together the subject’s adherence for each 
glaucoma medication and dividing it by the number of glaucoma medications the subject 
was using.
Analysis
We set the a priori level of statistical significance at p < 0.05. First, we ran descriptive 
statistics. Second, we examined the bivariate relationships between variables using Pearson 
correlation coefficients, chi-square statistics, and t-tests as appropriate. We conducted 
multivariable regression to examine how patient age, gender, race, glaucoma medication 
adherence self-efficacy, glaucoma outcome expectations, whether the patient was newly 
prescribed glaucoma medication on the day of the video-taped visit, number of glaucoma 
medications the patient was on, whether the physician educated about glaucoma, whether the 
physician educated about adherence and adherence strategies, whether the physician 
educated about how to administer the eye drops, whether the physicians educated about the 
purpose of the medication, whether the physician educated about side effects, whether the 
patient asked a question about glaucoma, whether the patient asked a question about 
glaucoma medications, physician age, and physician gender were associated with: (a) 
whether the patient was 80% or more adherent to their glaucoma medications, (b) the 
percent doses taken on time, and (c) the percent correct number of doses taken each day 
according to the MEMS caps during the 60 day period after the video-taped visit. Physician 
race could not be included in the multivariable analysis because there was only one non-
White physician.
Results
Fifteen physicians who cared for glaucoma patients agreed to participate in the study; one 
physician refused to participate for a participation rate of 94%. Fourteen physicians were 
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White and one was African American. Ten physicians were male (66.7%). Physician age 
ranged from 26 to 66 years (mean 40.8 years, standard deviation 11.7 years).
Eighty-six percent (N=279) of eligible patients who came to the research assistant to learn 
more about the study, enrolled in the study. We do not have information on the 
characteristics of those who chose not to participate. We had useable video-tapes on 276 out 
of the 279 patients. Eighty-nine percent of the enrolled patients had MEMS caps data for the 
60 day period after their video-taped visit (N=249). Those who did not have data either did 
not return their caps (N=24) or if they returned their MEMS caps, there was not useable data 
(N=6) (e.g. data was not downloadable due to hardware problems in the caps).
Table 1 presents the patient demographics. Forty-one percent of the sample was male and 
35.5% were African American. Eighteen percent of patients were prescribed glaucoma 
medications for the first time. Of those already on glaucoma medications, 20.6% (47) used 
them less than 6 months, 25.4% (58) used them 6 months to 2 years, 19.7% (45) used them 
more than 2 years to less than 5 years, and 34.2% (78) used them 5 years or longer.
As we reported elsewhere, providers educating patients about glaucoma occurred during 
approximately two-thirds of the visits.38 Provider education about using drops occurred 
during only 14% of the visits, adherence and adherence monitoring strategies during 18.3% 
of visits, the purpose of the medication during 17.6% of visits, and side effects during 27.2% 
of visits.8
Table 2 presents the multivariable logistic regression results predicting whether patients took 
80% or more of their prescribed doses of their glaucoma medications during the 60 day 
period after the video-taped visit. Patients who had higher glaucoma medication adherence 
self-efficacy were significantly more likely to be 80% or more adherent to their medications 
(odds ratio=1.09, 95% confidence interval=1.02, 1.17). African American patients were 
significantly less likely to be 80% or more adherent to their medications than non-African 
American patients (odds ratio=0.37, 95% confidence interval=0.16, 0.86).
Table 3 presents the multivariable linear regression results predicting the percent of doses 
patients took on time. Patients with higher glaucoma medication adherence self-efficacy 
(beta=0.20, p=0.005) were significantly more likely to take their doses on time. Patients on 
more glaucoma medications (beta= −0.21, p=0.002) were significantly less likely to take 
their doses on time. If physicians educated about how to administer the glaucoma eye drops 
(beta=0.15, p=0.02), the patients were significantly more likely to take their doses on time.
Table 3 presents the multivariable linear regression results predicting the percent correct 
number of doses taken each day. African American patients (beta= −0.16, p=0.01), patients 
newly prescribed glaucoma medications (beta= −0.16, p=0.03), and patients on more 
glaucoma medications (beta= −0.16, p=0.02) were significantly less likely to take the correct 
number of prescribed doses each day. Patients with higher glaucoma medication self-
efficacy (beta=0.20, p=0.005) and outcome expectations (beta= 0.16, p=0.03) were 
significantly more likely to take the correct number of prescribed doses each day. If 
physicians educated patients about how to administer their glaucoma eye drops (beta= 0.18, 
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p=0.008), patients were significantly more likely to take the correct number of prescribed 
doses each day.
Discussion
Whether physicians educated patients about how to administer their drops during visits was 
significantly associated with both whether patients took their drops on time and with 
whether they took the correct number of doses each day. Provider education about using 
drops occurred during only 14% of the visits.38 Providers educating patients about how to 
administer their drops included statements such as telling them to lean back their head, 
suggesting they use a mirror, giving them tips on how to get the drop in the eye, and telling 
patients how long to wait between administering two different eye drops. This suggests that 
providers should consider taking the time to educate patients about how to administer their 
drops. Educating patients about how to administer their eye drops could improve glaucoma 
medication adherence self-efficacy or confidence in using and taking their drops.
Educating patients about glaucoma occurred during approximately two-thirds of the visits38 
and was not significantly associated with whether patients took their doses on time during 
the 60 day period after the visit. The provider educating about side effects, adherence, or the 
purpose of the medication were not significantly associated with whether patients took their 
doses on time during the 60 day period after the visit. The physician educating about how to 
administer the eye drops was the only provider communication variable that was 
significantly associated with adherence.
Similar to prior research which has found that African Americans are less adherent to 
glaucoma medications than Caucasians20, 39–41, we did find that African Americans were 
significantly less likely to take 80% or more of their prescribed doses. Also, we did find that 
African Americans were significantly less likely to take the prescribed number of doses each 
day. This finding emphasizes the importance of providers educating African American 
patients about the importance of when to take their glaucoma medications each day and how 
many doses to take each day.
Patients asked one or more questions about glaucoma during 48% of visits.42 The number of 
questions about glaucoma asked by the patients during their medical visit ranged from 0 to 
17 (mean 1.3, standard deviation 2.0). Patients asked one or more questions about glaucoma 
medications during 59% of visits.42 The number of questions about glaucoma medications 
that patients asked during their medical visit ranged from 0 to 16 (mean 1.7, standard 
deviation 2.4).
Unlike prior research17, we did not find that patient question-asking during their visits was 
associated with medication adherence. A prior study found that patients who reported being 
less likely to ask their eye doctor questions during visits also reported being less adherent to 
their glaucoma medications.17 The difference in findings might be due to the fact that we 
examined actual patient question-asking whereas the other study was based on patient self-
report.
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Patient reported glaucoma medication self-efficacy was significantly associated with all of 
the adherence measures. This finding is important because it relates and therefore 
emphasizes the importance of patient self-efficacy, or self-confidence, in using glaucoma 
medications to patient adherence. The patient self-efficacy scale could be used as a tool by 
providers to assess when patients do not feel comfortable using glaucoma medications under 
certain circumstances (e.g. when traveling, when they experience side effects). Providers 
could use the patient responses to help them problem solve and boost patients confidence in 
using eye drops under these circumstances.
Higher glaucoma patient outcome expectations were significantly associated with the patient 
being more likely to take the correct number of doses each day. Patient outcome 
expectations are posited under Social Cognitive Theory to influence patient behaviors such 
as taking medications30, 31 and prior work in pediatric asthma did find outcome expectations 
to be positively associated with patient adherence.32 We did find evidence that glaucoma 
patient outcome expectations was significantly associated with one of the adherence 
measures that we examined in the current study. More research is needed to further explore 
how glaucoma patient outcome expectations are associated with adherence.
The self-efficacy and outcome expectations scales could be used in other types of glaucoma 
research and by glaucoma clinics. Our patients had relatively high scores on the self-efficacy 
and outcome expectation scales so future research should examine how self-efficacy and 
outcome expectation might be associated with adherence among patients with lower scores.
Patients on more complex regimens were less likely to take their doses on time and they 
were less likely to take the correct number of prescribed doses each day. This finding 
emphasizes the importance of ophthalmologists simplifying patients’ medication regimens if 
they can.
This study has several limitations. Providers and patients both knew the visit was being 
recorded but they did not know the study hypotheses. Our study is limited in that we could 
not track the characteristics of non-participants so we cannot compare the characteristics of 
participants and non-participants. Additionally, our coders counted the patient being 
educated about glaucoma or glaucoma medications during visits regardless of whether a 
physician, technician, or fellow provided it. A limitation is that we coded the data this way 
so we cannot separate out physician, technician, and fellow provision of education. Another 
limitation of our study is the lack of variation in physician race and how race might affect 
physician-patient communication and adherence. Despite these limitations, this prospective 
cohort study presents new information on provider-patient communication, self-efficacy, 
outcome expectations, and glaucoma patient medication adherence.
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  Male 40.9 (114)
  Female 59.1 (165)
Race
  African American 35.5 (99)
  Non-African American 64.2 (179)
Newly prescribed glaucoma medications at visit or was on glaucoma medication before visit
  Newly prescribed at visit 18.3 (51)
  Was on glaucoma medications before visit 81.7 (228)
Range; Mean (Standard Deviation)
Age 21 to 93; 65.8 (12.8)
Glaucoma medication adherence self-efficacy 28 to 63; 58.9 (5.5)
Glaucoma outcomes expectations 19 to 36; 34.5 (3.1)
Number of glaucoma medications 1 to 4; 1.4 (0.6)
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Table 2
Multivariable logistic regression results predicting whether the patient is 80% or more adherent during the 60-
day period after the visit according to MEMS caps (N=230)
Independent variables Patient is 80% or more adherent
OR (95% CI)
Patient age 1.01 (0.98, 1.04)
Patient gender-female 0.91 (0.40, 2.04)
Patient race-African American 0.37 (0.16, 0.86)*
Glaucoma medication adherence self-efficacy 1.09 (1.02, 1.17)*
Glaucoma outcome expectations 0.99 (0.87, 1.14)
Newly prescribed glaucoma medications 0.42 (0.13, 1.40)
Number of glaucoma medications 0.54 (0.28, 1.04)
Did physician educate about glaucoma 1.06 (0.39, 2.86)
Did physician educate about glaucoma adherence 0.97 (0.31, 3.05)
Did physician educate about the how to administer glaucoma medications 2.17 (0.53, 8.98)
Did physician educate about the purpose of the medications 0.52 (0.16, 1.62)
Did the physician educate about side effects 1.31 (0.44, 3.87)
Does the patient ask one or more questions about glaucoma 0.62 (0.27, 1.45)
Does the patient ask one or more questions about glaucoma medications 1.26 (0.54, 2.96)
Physician age 0.86 (0.28, 2.67)
Physician gender-female 1.00 (0.95, 1.05)
OR=Odds Ratio, 95%CI=95%, Confidence Interval;
*
p<0.05
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Table 3
Multivariable linear regression results predicting the percent doses taken on time and the percent correct 
number of doses taken each day during the 60 day period after the visit according to MEMS caps (N=230)







Patient age 0.11 0.02
Patient gender-female −0.01 0.01
Patient race-African American −0.13 −0.16*
Glaucoma medication adherence self-efficacy 0.20** 0.20**
Glaucoma outcome expectations 0.11 0.16*
Newly prescribed glaucoma medications −0.09 −0.16*
Number of glaucoma medications −0.21** −0.16*
Did physician educate about glaucoma 0.09 0.06
Did physician educate about adherence −0.05 −0.04
Did physician educate about how to administer glaucoma medications 0.15* 0.18**
Did physician educate about the purpose of the medications −0.06 −0.09
Did the physician educate about side effects 0.06 0.11
Does the patient ask one or more questions about glaucoma −0.10 −0.09
Does the patient ask one or more questions about glaucoma medications 0.02 −0.02
Physician age −0.04 −0.04
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